300595 欧普康视
已收盘 12-29 15:00:00
资讯
新帖
简况
欧普康视(300595)披露全资子公司对外提供财务资助的进展公告,12月26日股价下跌0.4%
证券之星 · 12-26 22:55
欧普康视(300595)披露全资子公司对外提供财务资助的进展公告,12月26日股价下跌0.4%
欧普康视:截止到2025年12月19日股东总人数为61,914户
证券之星 · 12-25
欧普康视:截止到2025年12月19日股东总人数为61,914户
欧普康视(300595)12月19日股东户数6.19万户,较上期减少0.02%
证券之星 · 12-23
欧普康视(300595)12月19日股东户数6.19万户,较上期减少0.02%
欧普康视:眼科手术机器人处于临床试验阶段
证券之星 · 12-23
欧普康视:眼科手术机器人处于临床试验阶段
欧普康视:盐酸毛果芸香碱滴眼液刚获临床试验批准
证券之星 · 12-23
欧普康视:盐酸毛果芸香碱滴眼液刚获临床试验批准
欧普康视(300595)股东南京欧陶信息科技有限公司质押10000股,占总股本0%
证券之星 · 12-18
欧普康视(300595)股东南京欧陶信息科技有限公司质押10000股,占总股本0%
欧普康视(300595)12月10日股东户数6.19万户,较上期增加0.08%
证券之星 · 12-15
欧普康视(300595)12月10日股东户数6.19万户,较上期增加0.08%
欧普康视(300595.SZ):盐酸毛果芸香碱滴眼液获得药物临床试验批准
智通财经 · 12-05
欧普康视(300595.SZ):盐酸毛果芸香碱滴眼液获得药物临床试验批准
欧普康视:参股企业将推音频类眼镜
证券之星 · 12-04
欧普康视:参股企业将推音频类眼镜
欧普康视:巩膜镜目前还是自费产品
证券之星 · 12-03
欧普康视:巩膜镜目前还是自费产品
欧普康视:截止到2025年11月28日股东总人数为61,877户
证券之星 · 12-02
欧普康视:截止到2025年11月28日股东总人数为61,877户
欧普康视(300595)11月20日股东户数6.22万户,较上期减少1.11%
证券之星 · 11-24
欧普康视(300595)11月20日股东户数6.22万户,较上期减少1.11%
欧普康视:前三季度视光终端收入占比提升至57.70%
证券之星 · 11-19
欧普康视:前三季度视光终端收入占比提升至57.70%
股市必读:欧普康视(300595)11月14日董秘有最新回复
证券之星 · 11-17
股市必读:欧普康视(300595)11月14日董秘有最新回复
欧普康视:离焦镜通过减少远视离焦减缓近视加深
证券之星 · 11-14
欧普康视:离焦镜通过减少远视离焦减缓近视加深
股市必读:欧普康视(300595)股东户数6.29万户,较上期增加1.3%
证券之星 · 11-13
股市必读:欧普康视(300595)股东户数6.29万户,较上期增加1.3%
欧普康视(300595)披露持股5%以上股东部分股份质押和解除质押公告,11月11日股价上涨1.3%
证券之星 · 11-11
欧普康视(300595)披露持股5%以上股东部分股份质押和解除质押公告,11月11日股价上涨1.3%
欧普康视:复合控框架眼镜已推出
证券之星 · 11-11
欧普康视:复合控框架眼镜已推出
欧普康视(300595)10月31日股东户数6.21万户,较上期增加1.81%
证券之星 · 11-04
欧普康视(300595)10月31日股东户数6.21万户,较上期增加1.81%
欧普康视:硬镜收入下降主因是片量下降所致
证券之星 · 10-29
欧普康视:硬镜收入下降主因是片量下降所致
加载更多
公司概况
公司名称:
欧普康视科技股份有限公司
所属行业:
专用设备制造业
上市日期:
2017-01-17
主营业务:
欧普康视科技股份有限公司的主营业务是眼健康和近视防控技术与服务。公司的主要产品是硬性接触镜类及其护理产品、硬镜以外的其它视光产品、其它眼健康产品。
发行价格:
23.81
{"stockData":{"symbol":"300595","market":"SZ","secType":"STK","nameCN":"欧普康视","latestPrice":14.88,"timestamp":1766991780000,"preClose":15.03,"halted":0,"volume":5917810,"delay":0,"changeRate":-0.01,"floatShares":668000000,"shares":894999999,"eps":0.5493,"marketStatus":"已收盘","change":-0.15,"latestTime":"12-29 15:00:00","open":15,"high":15.04,"low":14.85,"amount":88377000,"amplitude":0.0126,"askPrice":14.89,"askSize":487,"bidPrice":14.88,"bidSize":136,"shortable":0,"etf":0,"ttmEps":0.5493,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767058200000},"marketStatusCode":5,"adr":0,"adjPreClose":15.03,"symbolType":"stock","openAndCloseTimeList":[[1766971800000,1766979000000],[1766984400000,1766991600000]],"highLimit":16.53,"lowLimit":13.53,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":895289123,"isCdr":false,"pbRate":2.72,"roa":"--","peRate":27.089022,"roe":"9.13%","epsLYR":0.6408,"committee":0.206605,"marketValue":13322000000,"turnoverRate":0.0089,"status":1,"floatMarketCap":9947000000},"requestUrl":"/m/hq/s/300595","defaultTab":"news","newsList":[{"id":"2594294704","title":"欧普康视(300595)披露全资子公司对外提供财务资助的进展公告,12月26日股价下跌0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594294704","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594294704?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:55","pubTimestamp":1766760913,"startTime":"0","endTime":"0","summary":"公司于近日发布关于全资子公司对外提供财务资助的进展公告。公告显示,欧普康视科技股份有限公司于2024年3月29日审议通过全资子公司欧普投资向参股公司上海瑞影提供400万元财务资助的议案,借款期限至2025年12月31日,利率分为无息或单利10%,资金分批划转。截至公告日,欧普投资已收到上海瑞影归还的全部财务资助款项400万元,本次财务资助已全部收回。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600036973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2594816742","title":"欧普康视:截止到2025年12月19日股东总人数为61,914户","url":"https://stock-news.laohu8.com/highlight/detail?id=2594816742","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594816742?lang=zh_cn&edition=full","pubTime":"2025-12-25 11:33","pubTimestamp":1766633593,"startTime":"0","endTime":"0","summary":"证券之星消息,欧普康视(300595)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司,现在股份人数是多少?欧普康视回复:您好,截止到2025年12月19日,公司股东总人数为61,914户。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500013540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2593664496","title":"欧普康视(300595)12月19日股东户数6.19万户,较上期减少0.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593664496","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593664496?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:49","pubTimestamp":1766483390,"startTime":"0","endTime":"0","summary":"证券之星消息,近日欧普康视披露,截至2025年12月19日公司股东户数为6.19万户,较12月10日减少15.0户,减幅为0.02%。在医疗器械行业个股中,欧普康视股东户数高于行业平均水平,截至12月19日,医疗器械行业平均股东户数为2.19万户。从股价来看,2025年12月10日至2025年12月19日,欧普康视区间跌幅为2.91%,在此期间股东户数减少15.0户,减幅为0.02%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300028646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2593868462","title":"欧普康视:眼科手术机器人处于临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2593868462","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593868462?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:04","pubTimestamp":1766473482,"startTime":"0","endTime":"0","summary":"证券之星消息,欧普康视(300595)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,公司参股迪视医疗公司开发的眼科手术机器人,以及参股哈工艾斯德康公司开发的陪伴机器人,目前是否已上市?推广情况市场反应如何?欧普康视回复:您好,公司参股基金投资迪视医疗开发的眼科手术机器人,目前处于临床试验阶段;参股基金投资哈工艾斯德康开发的陪伴机器人,目前处于工程样机开发和验证阶段。目前两款产品尚未正式上市。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300018833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2593145443","title":"欧普康视:盐酸毛果芸香碱滴眼液刚获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593145443","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593145443?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:03","pubTimestamp":1766451792,"startTime":"0","endTime":"0","summary":"证券之星消息,欧普康视(300595)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,贵司盐酸毛果芸香碱滴眼液获批,请问预计2026年销售渠道主要有哪些?目前该类滴眼液市场情况如何?该产品获批上市预计对提升业绩是否有较大帮助?贵司对于同类老龄滴眼液如玻璃酸钠等是否有相关进度和安排?谢谢!欧普康视回复:您好,盐酸毛果芸香碱滴眼液刚获得临床试验批准,谈上市还早。药品的进展会按照规则披露。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300006402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2592977344","title":"欧普康视(300595)股东南京欧陶信息科技有限公司质押10000股,占总股本0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592977344","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592977344?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:47","pubTimestamp":1766054836,"startTime":"0","endTime":"0","summary":"证券之星消息,欧普康视12月18日公开信息显示,股东南京欧陶信息科技有限公司向招商证券股份有限公司合计质押1.0万股,占总股本0.0%。质押详情见下表:截止本公告日,股东南京欧陶信息科技有限公司已累计质押股份6830.5万股,占其持股总数的67.99%,股东合肥欧普民生投资管理合伙企业已累计质押股份350.0万股,占其持股总数的12.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800029148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2591121256","title":"欧普康视(300595)12月10日股东户数6.19万户,较上期增加0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591121256","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591121256?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:48","pubTimestamp":1765792080,"startTime":"0","endTime":"0","summary":"证券之星消息,近日欧普康视披露,截至2025年12月10日公司股东户数为6.19万户,较11月28日增加52.0户,增幅为0.08%。在医疗器械行业个股中,欧普康视股东户数高于行业平均水平,截至12月10日,医疗器械行业平均股东户数为2.19万户。从股价来看,2025年11月28日至2025年12月10日,欧普康视区间跌幅为1.53%,在此期间股东户数增加52.0户,增幅为0.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500022481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2589860774","title":"欧普康视(300595.SZ):盐酸毛果芸香碱滴眼液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589860774","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589860774?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:00","pubTimestamp":1764925250,"startTime":"0","endTime":"0","summary":"智通财经APP讯,欧普康视(300595.SZ)发布公告,公司于近日收到国家药品监督管理局下发的《药物临床试验批准通知书》(通知书编号:2025LP03261),批准公司的“盐酸毛果芸香碱滴眼液”开展临床试验。据悉,盐酸毛果芸香碱是M-胆碱受体激动剂,可激活平滑肌(例如虹膜括约肌和睫状肌)的毒蕈碱受体,通过虹膜括约肌的收缩,使瞳孔收缩,以增加焦深,改善近中视力,同时保持瞳孔对光的反应,另外其还可收缩睫状肌,增强适应力,从而达到治疗成人老花眼的效果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"欧普康视(300595.SZ):盐酸毛果芸香碱滴眼液获得药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2588722260","title":"欧普康视:参股企业将推音频类眼镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722260","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588722260?lang=zh_cn&edition=full","pubTime":"2025-12-04 11:36","pubTimestamp":1764819380,"startTime":"0","endTime":"0","summary":"证券之星消息,欧普康视(300595)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司AI眼镜.AI镜片研发进行到哪一步了,什么时候回上市!欧普康视回复:您好,公司参股的智能眼镜企业计划近期先推出可以日常佩戴使用的音频类眼镜。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400013393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2588060151","title":"欧普康视:巩膜镜目前还是自费产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2588060151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588060151?lang=zh_cn&edition=full","pubTime":"2025-12-03 08:48","pubTimestamp":1764722891,"startTime":"0","endTime":"0","summary":"证券之星消息,欧普康视(300595)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问:巩膜镜多用于矫正超高度近视(±2500度内)、圆锥角膜、角膜移植术后不规则散光及中重度干眼症。请问巩膜镜会不会列入上海、深圳或者广州的惠民保范围?公司在这方面可否做些工作?谢谢。欧普康视回复:您好,巩膜镜目前还是自费产品,是否能列入部分城市的惠民保范围,我们联合当地合作伙伴了解一下。谢谢您的建议!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300004393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2588977085","title":"欧普康视:截止到2025年11月28日股东总人数为61,877户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588977085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588977085?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:36","pubTimestamp":1764646587,"startTime":"0","endTime":"0","summary":"证券之星消息,欧普康视(300595)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问:截止11月底股东人数?欧普康视回复:您好,截止到2025年11月28日,公司股东总人数为61,877户。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200012936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2585468925","title":"欧普康视(300595)11月20日股东户数6.22万户,较上期减少1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585468925","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585468925?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:50","pubTimestamp":1763977828,"startTime":"0","endTime":"0","summary":"证券之星消息,近日欧普康视披露,截至2025年11月20日公司股东户数为6.22万户,较11月10日减少700.0户,减幅为1.11%。在医疗器械行业个股中,欧普康视股东户数高于行业平均水平,截至11月20日,医疗器械行业平均股东户数为2.2万户。从股价来看,2025年11月10日至2025年11月20日,欧普康视区间跌幅为3.37%,在此期间股东户数减少700.0户,减幅为1.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400022777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2584391913","title":"欧普康视:前三季度视光终端收入占比提升至57.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584391913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584391913?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:45","pubTimestamp":1763541912,"startTime":"0","endTime":"0","summary":"证券之星消息,欧普康视11月19日在投资者关系平台上答复投资者关心的问题。欧普康视回复:您好,前三季度公司控股的视光终端收入占总收入的比已从去年同期的53.01%提升至57.70%,终端数量也在增加;普通眼镜店取得巩膜镜零售资质可以配镜,不过,目前我们还是先重点开发专业视光渠道,因为他们技术力量较强,上手快;对于具备专业视光技术人员的非医疗视光服务机构,我们将强化培训巩膜镜验配技术,达到技术规范要求后将授权开展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900026027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2584693447","title":"股市必读:欧普康视(300595)11月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584693447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584693447?lang=zh_cn&edition=full","pubTime":"2025-11-17 03:29","pubTimestamp":1763321351,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,欧普康视报收于17.07元,下跌0.76%,换手率1.38%,成交量9.2万手,成交额1.58亿元。交易信息汇总资金流向11月14日主力资金净流出490.95万元;游资资金净流入505.38万元;散户资金净流出14.44万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700001213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2583528697","title":"欧普康视:离焦镜通过减少远视离焦减缓近视加深","url":"https://stock-news.laohu8.com/highlight/detail?id=2583528697","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583528697?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:37","pubTimestamp":1763091423,"startTime":"0","endTime":"0","summary":"证券之星消息,欧普康视11月14日在投资者关系平台上答复投资者关心的问题。这种减缓近视加深的机制最早来自于角膜塑形镜,其夜间配戴后在角膜上留下了一个“离焦环”,起到了减少周边远视离焦的作用,由于这个”离焦环”固定在角膜上,用眼时一直起作用,效果优于其它减离焦产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400014927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2583215302","title":"股市必读:欧普康视(300595)股东户数6.29万户,较上期增加1.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583215302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583215302?lang=zh_cn&edition=full","pubTime":"2025-11-13 03:46","pubTimestamp":1762976775,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘,欧普康视报收于17.19元,上涨0.35%,换手率1.7%,成交量11.39万手,成交额1.95亿元。来自股本股东变化:截至2025年11月10日,公司股东户数较前期增加1.3%,户均持股数量下降至1.42万股。交易信息汇总资金流向11月12日主力资金净流出740.16万元;游资资金净流出695.2万元;散户资金净流入1435.35万元。股本股东变化股东户数变动截至2025年11月10日,欧普康视股东户数为6.29万户,较10月31日增加806.0户,增幅1.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300004643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2582271362","title":"欧普康视(300595)披露持股5%以上股东部分股份质押和解除质押公告,11月11日股价上涨1.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582271362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582271362?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:15","pubTimestamp":1762870526,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘,欧普康视报收于17.13元,较前一交易日上涨1.3%,最新总市值为153.36亿元。公司近日发布公告称,持股5%以上股东南京欧陶信息科技有限公司将其持有的600万股公司股份质押给华龙证券股份有限公司,质押用途为资金需求。同时,南京欧陶解除此前质押给华龙证券的475万股股份。本次质押及解除质押后,南京欧陶累计质押股份68,295,000股,占其所持股份比例67.98%,占公司总股本比例7.63%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100040730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2582836913","title":"欧普康视:复合控框架眼镜已推出","url":"https://stock-news.laohu8.com/highlight/detail?id=2582836913","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582836913?lang=zh_cn&edition=full","pubTime":"2025-11-11 20:51","pubTimestamp":1762865499,"startTime":"0","endTime":"0","summary":"证券之星消息,欧普康视11月10日在投资者关系平台上答复投资者关心的问题。若有目前销售占比情况如何?另外并购的尚悦启程几月起计入合并口径报表,对三季报利润占比是多少?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100037993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2580778669","title":"欧普康视(300595)10月31日股东户数6.21万户,较上期增加1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580778669","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580778669?lang=zh_cn&edition=full","pubTime":"2025-11-04 17:27","pubTimestamp":1762248462,"startTime":"0","endTime":"0","summary":"证券之星消息,近日欧普康视披露,截至2025年10月31日公司股东户数为6.21万户,较10月20日增加1104.0户,增幅为1.81%。在医疗器械行业个股中,欧普康视股东户数高于行业平均水平,截至10月31日,医疗器械行业平均股东户数为2.2万户。从股价来看,2025年10月20日至2025年10月31日,欧普康视区间涨幅为3.54%,在此期间股东户数增加1104.0户,增幅为1.81%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400027504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2579917185","title":"欧普康视:硬镜收入下降主因是片量下降所致","url":"https://stock-news.laohu8.com/highlight/detail?id=2579917185","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579917185?lang=zh_cn&edition=full","pubTime":"2025-10-29 08:51","pubTimestamp":1761699071,"startTime":"0","endTime":"0","summary":"证券之星消息,欧普康视(300595)10月28日在投资者关系平台上答复投资者关心的问题。投资者提问:三季报经营分析中提到硬镜收入前三季度下降3.5%,单季收窄至1.9%,能否补充分析下硬镜用户数的增减情况?收入下跌主因是售价有所降低造成的还是用户数减少造成的?欧普康视回复:您好,主要是片量的下降所致,具体片量数据在年报中披露。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900013488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767009076085,"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0396},{"period":"3month","weight":-0.0877},{"period":"6month","weight":-0.0039},{"period":"1year","weight":-0.1902},{"period":"ytd","weight":-0.1923}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"欧普康视科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"61914人(较上一季度减少0.02%)","perCapita":"10797股","listingDate":"2017-01-17","address":"安徽省合肥市蜀山区高新区望江西路4899号","registeredCapital":"89528万元","survey":" 欧普康视科技股份有限公司的主营业务是眼健康和近视防控技术与服务。公司的主要产品是硬性接触镜类及其护理产品、硬镜以外的其它视光产品、其它眼健康产品。","listedPrice":23.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧普康视(300595)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧普康视(300595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧普康视,300595,欧普康视股票,欧普康视股票老虎,欧普康视股票老虎国际,欧普康视行情,欧普康视股票行情,欧普康视股价,欧普康视股市,欧普康视股票价格,欧普康视股票交易,欧普康视股票购买,欧普康视股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧普康视(300595)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧普康视(300595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}